It was observed that both antibodies could effectively clear HPA-1a–positive murine platelets from the circulation and prevent the occurrence of alloimmunization (determined by the presence of antibodies reactive against APLDQ platelets).

Source: https://seekingalpha.com/article/4587538-rallybio-corp-early-stage-developer-with-proof-of-concept-data?source=feed_all_articles